COVID-19 vaccination coverage among patients with psychiatric disorders in China during the pandemic: a cross-sectional study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      COVID-19*/prevention & control ; Vaccines* ; Mental Disorders*/epidemiology; Humans ; Pandemics ; Vaccination Coverage ; Cross-Sectional Studies ; COVID-19 Vaccines/therapeutic use ; China/epidemiology
    • Abstract:
      Background: To investigate the Coronavirus Disease 2019 (COVID-19) vaccination coverage and the influential factors of vaccination among patients with mental disorders, we conducted a cross-sectional study in China.
      Method: The anonymous questionnaires including demographic data, vaccination status, intention to be vaccinated and its reasons were collected in the Second Xiangya Hospital, one of the biggest four psychiatric centers in China. Mental health of these participants were measured by the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder-7 items (GAD-7). The influential factors associated with vaccination status were analyzed by Fisher exact tests and binary logistical analysis.
      Result: 1328 patients and 922 family members completed the survey. The vaccination rate of patients included was 69.4%, whereas 85.5% patients were willing to be vaccinated. Being hospitalized (aOR 0.41, 95% CI:0.27-0.60), suffering from schizophrenia (aOR 0.38, 95% CI: 0.19-0.75) and secondary school educational background (aOR 0.58, 95% CI: 0.37-0.93) were significantly associated with less likelihood to get vaccinated. Uptaking vaccines could reduce depressive (aOR 0.63, 95% CI: 0.41-0.98) or anxious symptoms (aOR 0.40, 95% CI: 0.25-0.63) in these patients for a short period.
      Conclusion: Further COVID-19 immunization programme should prioritize hospitalized psychiatric patients and schizophrenic patients since their demands for vaccination had been partly ignored during the current inoculation.
      (© 2022. The Author(s).)
    • References:
      Arch Intern Med. 2006 May 22;166(10):1092-7. (PMID: 16717171)
      Lancet Psychiatry. 2021 Sep;8(9):797-812. (PMID: 34274033)
      Front Psychiatry. 2022 Mar 25;13:806872. (PMID: 35401266)
      N Engl J Med. 2021 Sep 2;385(10):875-884. (PMID: 34233097)
      J Nerv Ment Dis. 2022 Apr 1;210(4):246-248. (PMID: 35349503)
      Vaccines (Basel). 2021 Sep 19;9(9):. (PMID: 34579281)
      Pediatrics. 2010 Dec;126(6):1117-23. (PMID: 21041282)
      Mol Neurodegener. 2021 Jul 19;16(1):48. (PMID: 34281568)
      Int J Biol Sci. 2020 Mar 15;16(10):1741-1744. (PMID: 32226293)
      Am J Transplant. 2021 Apr;21(4):1650-1656. (PMID: 33788992)
      Psychiatry Res. 2022 Jan;307:114329. (PMID: 34910966)
      Ann N Y Acad Sci. 2011 Aug;1231:17-22. (PMID: 21651565)
      BJPsych Open. 2021 Aug 11;7(5):e146. (PMID: 34422295)
      Vaccines (Basel). 2021 Dec 07;9(12):. (PMID: 34960190)
      JAMA Psychiatry. 2021 Jun 1;78(6):589-590. (PMID: 33320243)
      Am J Public Health. 2021 Jul;111(S2):S73-S74. (PMID: 34314215)
      Lancet Psychiatry. 2021 May;8(5):356-359. (PMID: 33609450)
      N Engl J Med. 2021 Jan 14;384(2):e6. (PMID: 33378604)
      JAMA. 2019 Dec 3;322(21):2125-2126. (PMID: 31626276)
      medRxiv. 2021 Apr 06;:. (PMID: 33564798)
      Nat Hum Behav. 2021 Apr;5(4):529-538. (PMID: 33686204)
      BMC Psychiatry. 2021 Sep 29;21(1):475. (PMID: 34587935)
      Depress Anxiety. 2012 Oct;29(10):906-13. (PMID: 22753313)
      BMC Public Health. 2022 Jan 18;22(1):126. (PMID: 35042506)
      Vaccines (Basel). 2021 Feb 16;9(2):. (PMID: 33669441)
      Front Psychol. 2021 May 25;12:622339. (PMID: 34113277)
      Transl Psychiatry. 2020 Jul 30;10(1):261. (PMID: 32732883)
      Int J Biol Sci. 2020 May 25;16(13):2265-2270. (PMID: 32760195)
      Nat Hum Behav. 2021 Jul;5(7):947-953. (PMID: 33972767)
      Front Psychol. 2020 Sep 09;11:2201. (PMID: 33013572)
      Gerontologist. 2021 Jan 21;61(1):103-113. (PMID: 33125065)
      World Psychiatry. 2021 Feb;20(1):124-130. (PMID: 33026219)
      BMJ Case Rep. 2013 Jun 11;2013:. (PMID: 23761569)
      Acta Neuropsychiatr. 2021 Oct;33(5):273-276. (PMID: 33998428)
      Lancet Psychiatry. 2021 Oct;8(10):901-908. (PMID: 34364406)
      Depress Anxiety. 2020 Jun;37(6):510-511. (PMID: 32383802)
      Lancet Psychiatry. 2021 Oct;8(10):860-861. (PMID: 34416185)
      PLoS One. 2021 Sep 8;16(9):e0256406. (PMID: 34496006)
      Ann Clin Psychiatry. 2017 Nov;29(4):227-234A. (PMID: 29069107)
      Acta Psychiatr Scand. 2020 Aug;142(2):152-153. (PMID: 32659855)
      Psychol Med. 2021 Jul;51(10):1773-1774. (PMID: 32326997)
      Sci Immunol. 2021 Jun 22;6(60):. (PMID: 34158390)
      World Psychiatry. 2021 Feb;20(1):53-54. (PMID: 33432762)
      JAMA Netw Open. 2020 Sep 1;3(9):e2023282. (PMID: 32997123)
      J Psychiatry Neurosci. 2021 Mar 05;46(2):E210-E211. (PMID: 33667055)
      Am J Prev Med. 2022 May;62(5):679-687. (PMID: 35012830)
    • Contributed Indexing:
      Keywords: COVID-19; Psychiatric disorder; Schizophrenia; Vaccination rates; Vaccine acceptance
    • Accession Number:
      0 (COVID-19 Vaccines)
      0 (Vaccines)
    • Publication Date:
      Date Created: 20221027 Date Completed: 20221028 Latest Revision: 20221104
    • Publication Date:
      20240628
    • Accession Number:
      PMC9597954
    • Accession Number:
      10.1186/s12888-022-04271-w
    • Accession Number:
      36289487